CRO Premier Research has appointed Martin Nicklasson, Ph.D., to its board of directors.

Nicklasson brings to Premier Research a wealth of international experience in the biopharmaceutical sector, both at the executive and at the board level. Nicklasson held positions in pharmaceutical development, R&D management and global marketing, as well as franchise management in Astra, Kabi Pharmacia and AstraZeneca. He became the CEO of AstraZeneca (Sweden) before moving on to the biotechnology sector as the CEO of Biovitrum.

He founded Nicklasson Life Science to support the growth and development of a series of biotechnology and specialty pharmaceutical companies, either as non-executive director or as chairman. Currently, Nicklasson chairs the board of directors of Basilea Pharmaceuticals, Orexo and Farma Holdings; he is a non-executive director of Biocrine, Pozen, and Oasmia.